marijuana stock news

Tilray to Report Fourth Quarter and Full Fiscal Year 2019 Financial Results on March 2, 2020

Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced today it will report results for the fourth quarter and full fiscal year ended December 31, 2019 on Monday, March 2, 2020 after market close.

The Company will host a conference call to discuss these results at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Monday, March 16, 2020, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international locations, and entering confirmation code 8197352.

There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived for 30 days.

About Tilray®

Tilray (Nasdaq: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 15 countries spanning five continents.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225006055/en/

Contacts

For further information:
Media, Global: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Rachel Perkins, +1-646-277-1221, rachel.perkins@icrinc.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$UTRM Retains the Auditing Services of Hartley Moore Accountancy Corporation

United Treatment Centers, Inc. Retains the Auditing Services of Hartley Moore Accountancy…

Jushi Holdings Inc. (JUSHF) Reports Second Quarter 2022 Financial Results

Jushi Holdings Inc. Reports Second Quarter 2022 Financial Results and Announces Non-Reliance…

Cara Therapeutics, Inc. (CARA) to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results…

GT Biopharma Inc. (GTBP) Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

GT Biopharma’s Chairman and Chief Executive Officer Provides Insight Into the Impact…